Abstract Importance: Blood-based biomarkers (BBMs) are transforming the diagnostic workflow for Alzheimer’s disease (AD). However, there is no consensus on the optimal phosphorylated tau (p-tau) isoform (217, 181, or 231) or analytical platform [mass spectrometry (MS) vs. immunoassay (IA)] for clinical implementation across different disease stages.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Xiaofen
Contact Xiaofen, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack